Blogs and updates

Recruitment and retention remain the two hardest problems in clinical research, and they are getting harder. For pharmaceutical sponsors and CRO clinical operations leaders running Phase II and III studies, weak clinical trial patient recruitment delays timelines, inflates costs, and produces...

In oncology, the gap between a signed contract and a fully activated site is where timelines quietly slip away. For pharmaceutical sponsors, CRO leaders, and biotech clinical operations teams running Phase II and III cancer studies, oncology site activation is one...

Choosing the right oncology clinical trial site can determine whether a study enrolls on time, retains patients, and produces clean data that holds up to regulatory scrutiny. For pharmaceutical sponsors and biotech clinical operations leaders, the decision goes far beyond geography....

Phase II and III trials are where sponsors commit the most time, capital, and scientific reputation, yet they are also where participant loss does the most damage. A study that enrolls slowly or bleeds participants midway through dosing can push timelines...

Retention is where many Phase II and III studies quietly lose ground, and it almost always traces back to how the study began. Strong patient retention in clinical trials depends less on chasing dropouts and more on building continuity from the...

The way sponsors design enrollment is shifting, and embedded research in clinical trials sits at the center of that change. Rather than asking patients to travel to dedicated research facilities, this approach folds studies into the everyday practices where people already...

Biotech trial recruitment has become the deciding factor in whether a study finishes on time or stalls in startup. For sponsors and clinical operations leaders, the question is no longer whether to outsource recruitment but which model actually reaches the patients...

Clinical trial data quality is essential to every successful clinical study. Accurate, timely, and inspection-ready information allows sponsors and CROs to evaluate safety, study performance, and clinical outcomes with confidence. However, clinical trial data quality does not result from a single...

Clinical trial enrollment remains one of the most persistent challenges in medical research. Sponsors and CROs may identify promising study locations, launch recruitment campaigns, and invest in outreach programs, yet many studies still struggle to connect with qualified participants. One reason...

Language differences are among the most persistent patient recruitment challenges in community-based clinical research. Potential participants must understand why a study is being conducted, what participation involves, how often they will need to attend visits, and what will happen during the...

Selecting the right clinical trial service partners can influence site activation, patient recruitment, quality, regulatory readiness, and overall study performance. The clinical research market includes several operating models. Some providers coordinate the complete study lifecycle, while others specialize in research sites,...

Patient recruitment can determine whether a clinical trial meets its enrollment goals, stays on schedule, and reaches the populations most relevant to the study. But effective recruitment is not simply about generating more leads. Sponsors need access to potentially eligible patients,...